TY - JOUR T1 - R3T (Rapid Research Response Team) One-step RT-qPCR kit for COVID-19 diagnostic using in-house enzymes JF - medRxiv DO - 10.1101/2020.07.31.20165704 SP - 2020.07.31.20165704 AU - Masateru Takahashi AU - Muhammad Tehseen AU - Rahul Salunke AU - Etsuko Takahashi AU - Sara Mfarrej AU - Mohamed A. Sobhy AU - Fatimah S. Alhamlan AU - Sharif Hala AU - Gerardo R. Mandujano AU - Ahmed A. Al-Qahtani AU - Fadwa S. Alofi AU - Afrah Alsomali AU - Anwar M. Hashem AU - Asim Khogeer AU - Naif A. M. Almontashiri AU - Jae Man Lee AU - Hiroaki Mon AU - Kosuke Sakashita AU - Mo Li AU - Takahiro Kusakabe AU - Arnab Pain AU - Samir M. Hamdan Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/04/2020.07.31.20165704.abstract N2 - One-step RT-qPCR is the most widely applied method for COVID-19 diagnostics. Designing in-house one-step RT-qPCR kits is restricted by the patent-rights for the production of enzymes and the lack of information about the components of the commercial kits. Here, we provide a simple, economical, and powerful one-step RT-qPCR kit based on patent-free, specifically-tailored versions of Moloney Murine Leukemia Virus Reverse Transcriptase and Thermus aquaticus DNA polymerase termed the R3T (Rapid Research Response Team) One-step RT-qPCR. Our kit was routinely able to reliably detect as low as 10 copies of the synthetic RNAs of the SARS-CoV-2. More importantly, our kit successfully detected COVID-19 in clinical samples of broad viral titers with similar reliability and selectivity as that of the Invitrogen SuperScript™ III Platinum™ One-step RT-qPCR and TaqPath™ 1-Step RT-qPCR kits. Overall, our kit has shown robust performance in both of laboratory settings and the Saudi Ministry of Health-approved testing facility.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by baseline funding from KAUST to Samir.M.Hmmdan and COVID-19 response initiative by the vice president of research at KAUST. The clinical COVID-19 samples were collected as part of KAUST baseline funding to Arnab Pain and the R3T initiative by the the vice president of research at KAUST. The authors declare no conflicts of interest.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Internal IBEC Comittees of each institution All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe included all data in the manuscript including Supplementary Figures and Table. ER -